Cytek Biosciences, Inc.2024财年第三财季实现净利润941000.00美元，同比增加114.57%

市场透视11-11

11月11日，Cytek Biosciences, Inc.（CTKB.US）公布财报，公告显示公司2024财年第三财季净利润为941000.00美元，同比增加114.57%；其中营业收入为51.50百万美元，同比增加7.29%，每股基本收益为0.01美元。从资产负债表来看，Cytek Biosciences, Inc.（CTKB.US）总负债1.06亿美元，其中短期债务8.02百万美元，资产负债...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482926207?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-11 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2482926207","market":"us","top_or_hot":-1,"title":"Cytek Biosciences, Inc.2024财年第三财季实现净利润941000.00美元，同比增加114.57%","media":"市场透视","content":"<div>\n<p>11月11日，Cytek Biosciences, Inc.（CTKB.US）公布财报，公告显示公司2024财年第三财季净利润为941000.00美元，同比增加114.57%；其中营业收入为51.50百万美元，同比增加7.29%，每股基本收益为0.01美元。从资产负债表来看，Cytek Biosciences, Inc.（CTKB.US）总负债1.06亿美元，其中短期债务8.02百万美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000233abb36391&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytek Biosciences, Inc.2024财年第三财季实现净利润941000.00美元，同比增加114.57%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytek Biosciences, Inc.2024财年第三财季实现净利润941000.00美元，同比增加114.57%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000233abb36391&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月11日，Cytek Biosciences, Inc.（CTKB.US）公布财报，公告显示公司2024财年第三财季净利润为941000.00美元，同比增加114.57%；其中营业收入为51.50百万美元，同比增加7.29%，每股基本收益为0.01美元。从资产负债表来看，Cytek Biosciences, Inc.（CTKB.US）总负债1.06亿美元，其中短期债务8.02百万美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000233abb36391&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTKB","symbol_name":"Cytek BioSciences","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000233abb36391&s=b","article_id":"2482926207","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000233abb36391&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2482926207","pubTimestamp":1731254508,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月11日，Cytek Biosciences, Inc.公布财报，公告显示公司2024财年第三财季净利润为941000.00美元，同比增加114.57%；其中营业收入为51.50百万美元，同比增加7.29%，每股基本收益为0.01美元。从资产负债表来看，Cytek Biosciences, Inc.总负债1.06亿美元，其中短期债务8.02百万美元，资产负债比为4.64，流动比率为0.07。机构评级：截至2024年11月11日，当前有5家机构对Cytek Biosciences, Inc.目标价做出预测，其中目标均价为8.10美元，其中最低目标价为7.00美元，最高目标价为9.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"CTKB":"Cytek BioSciences"},"translate_title":"Cytek Biosciences, Inc. achieved a net profit of US $941,000.00 in the third fiscal quarter of fiscal year 2024, a year-on-year increase of 114.57%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTKB":0.9},"content_text":"11月11日，Cytek Biosciences, Inc.（CTKB.US）公布财报，公告显示公司2024财年第三财季净利润为941000.00美元，同比增加114.57%；其中营业收入为51.50百万美元，同比增加7.29%，每股基本收益为0.01美元。从资产负债表来看，Cytek Biosciences, Inc.（CTKB.US）总负债1.06亿美元，其中短期债务8.02百万美元，资产负债比为4.64，流动比率为0.07。机构评级：截至2024年11月11日，当前有5家机构对Cytek Biosciences, Inc.目标价做出预测，其中目标均价为8.10美元，其中最低目标价为7.00美元，最高目标价为9.00美元。公司简介：Cytek Biosciences Inc 是一家细胞分析解决方案公司，通过利用新颖的技术方法推进下一代细胞分析工具。其核心仪器Cytek Aurora和Northern Lights系统是第一个全光谱流式细胞仪，能够通过利用来自多个激光器的全光谱荧光特征来区分单个细胞上的荧光标签，从而提供高分辨率，高含量和高灵敏度的细胞分析。公司的FSP平台解决了其他技术固有的局限性，通过提供更高的信息密度，更高的灵敏度，更大的灵活性和更高的效率，所有这些都能降低性能成本。从地理上看，该公司的大部分收入来自美国。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482926207"}